Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis

Authors: Bachert, Claus1; El-Akkad, Tarek2

Source: Annals of Allergy, Asthma and Immunology, Volume 89, Number 3, September 2002 , pp. 292-297(6)

Publisher: American College of Allergy, Asthma, & Immunology

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Although they have comparable safety and efficacy profiles, different intranasal corticosteroids possess different sensory/chemical properties that can be easily differentiated by patients, and which may influence their preference and compliance.

Objective: We sought to compare patient assessments of sensory attributes of three intranasal corticosteroid sprays: triamcinolone acetonide aqueous (TAA), fluticasone propionate (FP), and mometasone furoate (MF).

Methods: In a multicenter, randomized, double-blind, crossover study, 95 patients with allergic rhinitis rated 14 sensory items (100-point scales), product preference, and likelihood of compliance with treatment.

Results: Immediately after administration, compared with MF, TAA was rated as having significantly better comfort during administration, less irritation, less odor strength, preferred odor, more moistness of nose/throat, milder taste (allP le 0.001), and preferred taste (P le 0.01). Compared with FP, TAA was rated as having significantly less odor strength, preferred odor (both P le 0.001), more moistness of nose/throat (P le 0.01), and milder taste (P le 0.05). Two minutes after application, TAA was rated as having less aftertaste than FP (P le 0.01) or MF (P le 0.001), and produced significantly less irritation (FP P le 0.05; MF P le 0.01). Of patients, 54.7% said they would prefer a prescription of TAA over one for MF (24.2%; P = 0.001) or FP (21.1%;P = 0.001). More patients indicated that they would be more compliant with treatment if given the TAA prescription (67.4%) than if given a prescription with FP (54.7%) or MF (49.5%).

Conclusion: Several of the TAA sensory attributes were preferred over those of MF and FP. Patient preference may play a role in enhancing treatment compliance. Such findings indicate that TAA nasal spray may be a better choice than MF or FP in the treatment of seasonal and perennial allergic rhinitis.

Document Type: Original article

Affiliations: 1: Department of Ear, Nose, and Throat, University Hospital, Ghent, Belgium. 2: Aventis Pharmaceuticals, Bridgewater, New Jersey.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$28.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A